Financing ·
On September 11, 2026, Nautilus Biotechnology entered into a new Sales Agreement with TD Securities (USA), LLC to sell…
NAUTNautilus Biotechnology, Inc.
On September 11, 2026, Nautilus Biotechnology entered into a new Sales Agreement with TD Securities (USA), LLC to sell shares of its common stock through an at-the-market offering program with aggregate sales proceeds of up to $125,000,000. The company simultaneously terminated the prior Sales Agreement dated February 28, 2024, under which no shares had been sold. TD Securities will act as sales agent and is entitled to compensation equal to up to 3.0% of gross proceeds. Nautilus Biotechnology operates in the biotechnology industry, developing diagnostic tests for cancer.